


Over 3x Increase in Intra-tumoural Dose of cetuximab with SonoTran®

HT29 human colorectal cancer cell line



Mean whole tumour ELISA quantification, 5 x mice cetuximab group, 6 x mice cetuximab + SonoTran® group

About OxSonics

Since 2013, OxSonics has built a world-leading multi-disciplinary product development and commercialisation team that have successfully developed the SonoTran® Platform as a scalable commercial-grade product. We work closely with both medical oncologists and oncology radiologists to ensure our products are directed at the specific patient groups that stand to benefit most but also that our products fit seamlessly into existing patient care pathways in an oncology ward setting.

Today, SonoTran® is being evaluated clinically and we're working with multiple partners to tackle the toughest cancers, head on.

Partner with us

By combining your therapeutic agent with SonoTran® we could significantly de-risk your clinical development program and maximise its chances of delivering first-in-class and/or best-in-class therapy to patients. Importantly no drug reformulation is needed whatsoever.

By working with us, we can create new IP and optimal pricing and reimbursement that together provide a framework to bring better and smarter therapies to patients.

Call:

+44 (0) 1865 784777

Email:



nicholas.adams@oxsonics.com

OxSonics Ltd

The Magdalen Centre
Oxford Science Park
Robert Robinson Avenue
Oxford, OX4 4GA
UK

~30% of Mice were Tumour-free in the SonoTran® + cetuximab Group vs None in the cetuximab Group

Treatment of the human lung cancer cell line NCI-H292 with a suboptimal (i.e. single dose) cetuximab regime + SonoTran® led to a delay in tumour growth when compared to cetuximab antibody treatment alone. 2 out of 7 mice in the SonoTran® treated group were tumour-free vs none in the cetuximab only group.



Tumour volumes post treatment. Curves represent individual mice.

About OxSonics

Since 2013, OxSonics has built a world-leading multi-disciplinary product development and commercialisation team that have successfully developed the SonoTran® Platform as a scalable commercial-grade product. We work closely with both medical oncologists and oncology radiologists to ensure our products are directed at the specific patient groups that stand to benefit most but also that our products fit seamlessly into existing patient care pathways in an oncology ward setting.

Today, SonoTran® is being evaluated clinically and we're working with multiple partners to tackle the toughest cancers, head on.

Partner with us

By combining your therapeutic agent with SonoTran® we could significantly de-risk your clinical development program and maximise its chances of delivering first-in-class and/or best-in-class therapy to patients. Importantly no drug reformulation is needed whatsoever.

By working with us, we can create new IP and optimal pricing and reimbursement that together provide a framework to bring better and smarter therapies to patients.

Call:

+44 (0) 1865 784777

Email:

nicholas.adams@oxsonics.com

OxSonics Ltd

The Magdalen Centre
Oxford Science Park
Robert Robinson Avenue
Oxford, OX4 4GA
UK

www.oxsonics.com